Artemis Medicare Services Limited , a leading healthcare provider, has reported robust financial performance for the second quarter of fiscal year 2026, alongside announcing significant expansion plans that promise to reshape its market presence.

Strong Financial Performance

The company delivered a consolidated revenue of INR 274.70 crores in Q2 FY26, marking a 13.8% year-on-year growth. This impressive performance was driven by strong showings in key specialties including cardiac sciences, oncology, and neurosciences. The EBITDA margin stood at 21.2%, an improvement from 20.6% in the same quarter last year, indicating enhanced operational efficiency.

Key Financial Highlights

The company's profit after tax before exceptional items reached INR 30.00 crores, showcasing a substantial 35.6% year-on-year increase.

Operational Excellence

Artemis Medicare's flagship facility in Gurugram continued its growth trajectory, supported by an increase in international patients and capacity additions. The hospital reported an occupancy rate of 64.1%, while the Average Revenue Per Occupied Bed (ARPOB) reached INR 81,248, reflecting an improved case mix and a higher proportion of complex procedures.

Notably, the international business contributed approximately 32% of revenues, underlining the company's strong position in the medical value travel segment.

Expansion Plans

The company has outlined an expansion strategy:

1. Raipur Facility: A 300-bed hospital is on track for commissioning by March 2026.
2. South Delhi Project: A binding MoU has been signed for a 650-bed facility in South Delhi.
3. Gurgaon Expansion: Plans to increase capacity to 850-1,000 beds using additional FAR approvals.

Dr. Devlina Chakravarty, Managing Director of Artemis Medicare, stated, "Our focus remains on operational excellence, clinical depth, and disciplined growth. We are committed to expanding our capacity, improving margins, and driving digital innovation to deliver value to all our stakeholders."

Future Outlook

With these expansion plans, Artemis Medicare is positioned for potential growth in the coming years. The company's strategy of maintaining a strong presence in key specialties, coupled with its focus on the international patient segment, may strengthen its market position in the competitive healthcare market.

As the healthcare landscape continues to evolve, Artemis Medicare's investments in advanced medical technologies and expansion into new geographies are expected to contribute to its long-term value creation for shareholders.

Artemis Medicare Services Limited has taken a significant step in strengthening its capital structure by allotting 1.89 crore equity shares to the International Finance Corporation (IFC). This move comes as a result of the conversion of compulsorily convertible debentures (CCDs), marking a notable development in the company's financial landscape.

Key Details of the Allotment

• Shares Allotted: 1,89,62,247 equity shares
• Recipient: International Finance Corporation (IFC)
• Conversion Basis: 33,000 compulsorily convertible debentures
• Conversion Price: Rs. 174.03 per share
• Face Value of New Shares: Re. 1 each

Impact on Share Capital

The allotment has resulted in a significant increase in Artemis Medicare's paid-up equity share capital:

This expansion represents a 13.62% increase in the company's equity base.

Debenture Details

The converted debentures had the following characteristics:

• Number of CCDs: 33,000
• Face Value: Rs. 1,00,000 each
• Interest Rate: 2.65% per annum, compounded quarterly on a cumulative basis

Regulatory Compliance and Trading

The allotment adheres to SEBI regulations, particularly the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The newly issued shares will rank pari passu with existing equity shares and are set to be listed and traded on both the BSE Limited and the National Stock Exchange of India Limited, pending necessary approvals.

Strategic Implications

This conversion of debentures into equity represents a strategic move for Artemis Medicare. By bringing IFC, a reputed international financial institution, into its equity fold, the company may be positioning itself for potential growth and expansion. The increased equity base could provide more financial flexibility and potentially enhance the company's ability to pursue its business objectives.

Conclusion

The allotment of shares to IFC through the conversion of CCDs marks a significant corporate action for Artemis Medicare Services Limited. As the company's equity base expands, stakeholders will be keen to observe how this capital infusion influences the company's future strategies and financial performance in the healthcare sector.